Does Tipranavir Interact with Atorvastatin Calcium?
CDI records a contraindicated classification for Tipranavir and Atorvastatin Calcium. The stored summary is: Significantly increases atorvastatin plasma levels and increases myopathy/rhabdomyolysis risk. Concomitant use is not recommended. The mechanism involves inhibition of cyp3a4 and transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Tipranavir Class
- Protease Inhibitor
- Atorvastatin Calcium Class
- HMG-CoA Reductase Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of CYP3A4 and transporters
What To Tell Your Doctor or Pharmacist
If you are taking Tipranavir and your doctor is considering prescribing Atorvastatin Calcium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider